DURECT Corp. (DRRX:NASDAQ)) announced in a news release that dosing began for its Phase 2a trial evaluating topical DUR-928 as a treatment for mild to moderate plaque psoriasis. Twenty patients will be enrolled across multiple U.S. sites.
This is a significant milestone for the company with respect to DUR-928, as it aims to "produce data with the potential to create significant commercial and partnering value," President and CEO James Brown said in the release.
In this randomized, double-blind study, patients will, once a day, apply DUR-928 to the plaque on one arm and the vehicle to similar plaque on their other arm, for four weeks. After the treatment period ends, patients will be followed for four weeks. The primary efficacy endpoint will be change in local psoriasis scores from baseline of the plaque treated with DUR-928 versus that of the plaque treated with the vehicle.
DURECT expects to announce topline data from this proof-of-concept trial in H2/19.
In other news, the company will host a conference call at 11 a.m. EST on March 29, 2019, in which Dr. Howard Maibach, professor of dermatology and practicing dermatologist at the University of California, San Francisco, will give an overview of psoriasis and the landscape for topical medications as a treatment for the condition. Also during the call, DURECT will review its development plan for DUR-928.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: DURECT Corp. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
